A Study of CTD402 in T-ALL/LBL Patients

Key Inclusion Criteria:

1. Male or female, ≥ 12 years of age.

2. Participants with body weight ≥ 40 kilogram.

3. Relapsed or refractory T-ALL/LBL is defined as one of the following:

4. Relapsed or refractory disease after two or more lines of systemic therapy;

5. The first relapse occurs within 12 months after first remission;

6. Relapse after allogeneic HSCT and must be ≥100 days from HSCT prior toscreening period.

7. The presence of bone marrow lymphoblasts is ≥ 5% as determined by morphologicevaluation or evidence of extramedullary disease at screening.

8. Have eligible HLA-matched related donor (MRD) or unrelated donor (URD), eligiblehaploidentical donor (HID) or syngeneic donors.

9. Adequate organ function

10. Karnofsky PS ≥ 60 (for participants age ≥ 16) or Lansky PS ≥ 60 (for participants <

16. at screening.

Key Exclusion Criteria:

1. Participants with concomitant genetic syndromes associated with bone marrow failurestates or any other known bone marrow failure syndrome.

2. Active central nervous system (CNS) involvement

3. Participants with following cardiac conditions will be excluded:

4. History of heart failure New York Heart Association (NYHA) class III or IV;

5. History of myocardial infarction, cardiovascular angioplasty or stenting,unstable angina, or other serious heart diseases within 12 months ofenrollment.

6. Primary immune deficiency.

7. Presence of uncontrolled infections.

8. Known history of infection with the human immunodeficiency virus (HIV); hepatitis Cvirus and syphilis.

9. Active or latent hepatitis B virus infection

10. Epstein-Barr virus (EBV), Cytomegalovirus (CMV) DNA or IgM positive at screening.